LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

433.1 -0.04

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

432.05

Max

438.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	-160M 1B
Verkäufe	-240M 3B
KGV Branchendurchschnitt	25.91 49.701
EPS	4.47
Gewinnspanne	34.531
Angestellte	6,400
EBITDA	-215M 1.1B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+29.84% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.4B 111B
Vorheriger Eröffnungskurs	433.14
Vorheriger Schlusskurs	433.1

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

428.545 / 498.65 Unterstützung & Widerstand

Vertex Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Vertex Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

29.84% Vorteil

12-Monats-Prognose

Durchschnitt 562.9 USD 29.84%

Hoch 641 USD

Tief 436 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vertex Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

24 ratings

Buy

Halten

Sell

Basierend auf 24 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vertex Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

428.545 / 498.65Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.